Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sonoma Pharmaceuticals Inc's Business Segments
Sonoma Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2026
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 4
Regions Reported
-
Sonoma Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - Q3 FY2026
- Product88.8%
Revenue by Product & Service Category - Q3 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 4 | 88.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals Inc is a global specialty pharmaceutical company that develops, manufactures, and markets unique and effective products to treat various dermatological conditions and advanced tissue care. The company is dedicated to providing innovative solutions in the fields of dermatology, wound care, and advanced tissue care.
Sonoma Pharmaceuticals focuses on developing products that aim to improve patient outcomes and enhance the quality of life for those suffering from dermatological conditions. Their products utilize advanced hypochlorous acid (HOCl) technology, which is a naturally occurring molecule with antimicrobial properties. This technology allows for the development of safe and effective solutions that can manage infections, inflammation, and promote wound healing without causing any harm to the skin or tissues.
One of the key areas of focus for Sonoma Pharmaceuticals is dermatology. They offer a range of prescription and over-the-counter dermatological products that cater to various skin conditions such as acne, rosacea, eczema, dermatitis, and fungal infections. These products are designed to effectively manage symptoms, reduce inflammation, and promote skin health.
In the field of wound care, Sonoma Pharmaceuticals provides advanced wound care products that are designed to accelerate healing, reduce infection, and provide a moist wound healing environment. Their portfolio includes products for acute and chronic wounds, burns, surgical wounds, diabetic foot ulcers, and venous leg ulcers. These products facilitate the healing process, prevent complications, and improve overall wound care outcomes.
Moreover, Sonoma Pharmaceuticals also offers products for advanced tissue care. This includes solutions for managing irritations, itchiness, and inflammation of the eye and eyelids. Their ophthalmic products offer relief from dry eye symptoms, blepharitis, and conjunctivitis.
Sonoma Pharmaceuticals operates worldwide, catering to healthcare professionals, dermatologists, wound care specialists, ophthalmologists, and patients seeking effective dermatological and wound care solutions. They have built a strong reputation for their commitment to quality, innovation, and clinical excellence.
The company has a strong research and development team that continually works on advancing their technology and developing new products. They conduct extensive clinical trials and collaborate with key opinion leaders to ensure the safety, efficacy, and regulatory compliance of their products.
Overall, Sonoma Pharmaceuticals Inc is a leading specialty pharmaceutical company that is dedicated to providing innovative and effective solutions for dermatological conditions and advanced tissue care. They strive to improve patient outcomes, enhance quality of life, and set new standards in the field of dermatology and wound care.
Sonoma Pharmaceuticals focuses on developing products that aim to improve patient outcomes and enhance the quality of life for those suffering from dermatological conditions. Their products utilize advanced hypochlorous acid (HOCl) technology, which is a naturally occurring molecule with antimicrobial properties. This technology allows for the development of safe and effective solutions that can manage infections, inflammation, and promote wound healing without causing any harm to the skin or tissues.
One of the key areas of focus for Sonoma Pharmaceuticals is dermatology. They offer a range of prescription and over-the-counter dermatological products that cater to various skin conditions such as acne, rosacea, eczema, dermatitis, and fungal infections. These products are designed to effectively manage symptoms, reduce inflammation, and promote skin health.
In the field of wound care, Sonoma Pharmaceuticals provides advanced wound care products that are designed to accelerate healing, reduce infection, and provide a moist wound healing environment. Their portfolio includes products for acute and chronic wounds, burns, surgical wounds, diabetic foot ulcers, and venous leg ulcers. These products facilitate the healing process, prevent complications, and improve overall wound care outcomes.
Moreover, Sonoma Pharmaceuticals also offers products for advanced tissue care. This includes solutions for managing irritations, itchiness, and inflammation of the eye and eyelids. Their ophthalmic products offer relief from dry eye symptoms, blepharitis, and conjunctivitis.
Sonoma Pharmaceuticals operates worldwide, catering to healthcare professionals, dermatologists, wound care specialists, ophthalmologists, and patients seeking effective dermatological and wound care solutions. They have built a strong reputation for their commitment to quality, innovation, and clinical excellence.
The company has a strong research and development team that continually works on advancing their technology and developing new products. They conduct extensive clinical trials and collaborate with key opinion leaders to ensure the safety, efficacy, and regulatory compliance of their products.
Overall, Sonoma Pharmaceuticals Inc is a leading specialty pharmaceutical company that is dedicated to providing innovative and effective solutions for dermatological conditions and advanced tissue care. They strive to improve patient outcomes, enhance quality of life, and set new standards in the field of dermatology and wound care.
Sonoma Pharmaceuticals, Inc. specializes in the development and commercialization of innovative pharmaceutical products, particularly in the fields of dermatology and ophthalmology. The company focuses on leveraging its proprietary technologies to create effective therapies with the aim of enhancing patient care in various medical conditions. Below are key segments, products, and services offered by Sonoma Pharmaceuticals:
Segments
1. Dermatology:
- Sonoma develops treatments primarily aimed at skin conditions. Their products are designed to address various dermatological issues, including chronic wounds, atopic dermatitis, and acne. The emphasis is on developing formulations that promote healing and improve the quality of life for patients suffering from problematic skin conditions.
2. Ophthalmology:
- In this segment, Sonoma focuses on therapies for eye conditions, notably dry eye disease and other related ocular disorders. Their products aim to lubricate and protect the eye surface, alleviating symptoms of discomfort and irritation.
Products
1. SNP-1:
- A proprietary formulation focused on treating certain dermatological conditions, SNP-1 is designed to enhance healing processes, reduce inflammation, and combat infections in skin lesions.
2. SNP-2:
- This product targets microbial infections and is formulated to offer both antibacterial effects and support the skins natural healing mechanisms. Its often utilized for chronic wounds and more acute dermatological issues.
3. Avenova:
- Avenova is a unique antimicrobial solution targeting the eyelid and lash area. It’s specifically formulated to manage blepharitis, a common condition that can lead to inflammation and discomfort.
4. PuraStat:
- PuraStat is a topical solution aimed at promoting hemostasis in surgical settings, assisting in the control of bleeding during various procedures. Its design enables it to be easily applied in clinical environments.
Services
1. Clinical Development:
- Sonoma Pharmaceuticals is involved in extensive clinical trials to validate the safety and efficacy of its products. They focus on addressing unmet medical needs through innovative development programs.
2. Regulatory Affairs:
- The company provides regulatory support to ensure compliance with the appropriate health authorities for drug approvals. This includes navigating complex pathways for both new and existing pharmaceutical products.
3. Commercialization:
- Sonoma engages in commercial strategies to promote its products, forming partnerships with healthcare providers and distributors. Their commercialization efforts help ensure that their innovations reach the intended patient populations effectively.
4. Research and Development:
- Continuous R&D efforts are a hallmark of Sonomas approach, with an emphasis on improving existing formulations and exploring new therapeutic areas. The company seeks to expand its portfolio through both in-house development and potential partnerships.
Treatment Areas
- Chronic Wounds: Treating slow-healing wounds and conditions that require advanced therapeutic interventions to promote healing.
- Dry Eye Disease: Addressing symptoms of dryness, irritation, and discomfort in the eyes, enhancing quality of life for individuals with chronic eye conditions.
- Skin Infections: Providing effective antimicrobial solutions for treating various skin infections while fostering rapid healing of affected areas.
Target Markets
Sonoma Pharmaceuticals targets healthcare providers, including dermatologists and ophthalmologists, as well as hospitals and surgical centers where their products are utilized. Their commitment to innovation aims to address significant gaps in treatment options for common skin and eye conditions, positioning the company favorably in niche markets within the pharmaceutical industry.
By aligning their product development with patient needs and leveraging new technologies, Sonoma Pharmaceuticals continues to advance both its offerings and market presence in the pharmaceutical landscape, with a clear focus on improving patient outcomes across its segments.
Segments
1. Dermatology:
- Sonoma develops treatments primarily aimed at skin conditions. Their products are designed to address various dermatological issues, including chronic wounds, atopic dermatitis, and acne. The emphasis is on developing formulations that promote healing and improve the quality of life for patients suffering from problematic skin conditions.
2. Ophthalmology:
- In this segment, Sonoma focuses on therapies for eye conditions, notably dry eye disease and other related ocular disorders. Their products aim to lubricate and protect the eye surface, alleviating symptoms of discomfort and irritation.
Products
1. SNP-1:
- A proprietary formulation focused on treating certain dermatological conditions, SNP-1 is designed to enhance healing processes, reduce inflammation, and combat infections in skin lesions.
2. SNP-2:
- This product targets microbial infections and is formulated to offer both antibacterial effects and support the skins natural healing mechanisms. Its often utilized for chronic wounds and more acute dermatological issues.
3. Avenova:
- Avenova is a unique antimicrobial solution targeting the eyelid and lash area. It’s specifically formulated to manage blepharitis, a common condition that can lead to inflammation and discomfort.
4. PuraStat:
- PuraStat is a topical solution aimed at promoting hemostasis in surgical settings, assisting in the control of bleeding during various procedures. Its design enables it to be easily applied in clinical environments.
Services
1. Clinical Development:
- Sonoma Pharmaceuticals is involved in extensive clinical trials to validate the safety and efficacy of its products. They focus on addressing unmet medical needs through innovative development programs.
2. Regulatory Affairs:
- The company provides regulatory support to ensure compliance with the appropriate health authorities for drug approvals. This includes navigating complex pathways for both new and existing pharmaceutical products.
3. Commercialization:
- Sonoma engages in commercial strategies to promote its products, forming partnerships with healthcare providers and distributors. Their commercialization efforts help ensure that their innovations reach the intended patient populations effectively.
4. Research and Development:
- Continuous R&D efforts are a hallmark of Sonomas approach, with an emphasis on improving existing formulations and exploring new therapeutic areas. The company seeks to expand its portfolio through both in-house development and potential partnerships.
Treatment Areas
- Chronic Wounds: Treating slow-healing wounds and conditions that require advanced therapeutic interventions to promote healing.
- Dry Eye Disease: Addressing symptoms of dryness, irritation, and discomfort in the eyes, enhancing quality of life for individuals with chronic eye conditions.
- Skin Infections: Providing effective antimicrobial solutions for treating various skin infections while fostering rapid healing of affected areas.
Target Markets
Sonoma Pharmaceuticals targets healthcare providers, including dermatologists and ophthalmologists, as well as hospitals and surgical centers where their products are utilized. Their commitment to innovation aims to address significant gaps in treatment options for common skin and eye conditions, positioning the company favorably in niche markets within the pharmaceutical industry.
By aligning their product development with patient needs and leveraging new technologies, Sonoma Pharmaceuticals continues to advance both its offerings and market presence in the pharmaceutical landscape, with a clear focus on improving patient outcomes across its segments.